Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Stopped Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.

Conditions

• Endometrial Cancer
• Ovarian Cancer

Interventions

• DRUG: Copanlisib
• DRUG: fulvestrant

Sponsor

M.D. Anderson Cancer Center

Collaborators

• Bayer